We took the opportunity to catch-up with valued editorial board member, Angelo Antonini (University of Padova, Veneto, Italy). He shared an overview of one of the plenary sessions he participated in considering the recognition and treatment of complications in the later stages of Parkinson’s disease.
1. Describe the clinical profile of patients with late stage Parkinson’s disease (PD)? (0:05)
2. What is the optimum method of managing motor and non-motor fluctuations and dyskinesias in late stage PD? (1:36)
3. What behavioural, cognitive and psychiatric symptoms may occur in later stages of PD? (3:49)
4. What factors should be considered when optimising the medical management of psychiatric/cognitive disorders in patients with PD? (6:08)
5. What are the most common axial problems affecting gait in late stage PD, and how can these be treated? (7:22)
Speaker disclosure: Angelo Antonini has nothing relevant to disclose in relation to this video interview.
Filmed at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), Nice, France, September 2019.
Share this Video
Related Videos In Parkinson's Disease
Heinz Reichmann, EAN 2021: OPTIPARK Study Findings
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented […]
Heinz Reichmann, EAN 2021: Levodopa-based Drugs in the Treatment of Parkinson’s Disease
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology […]
Stephen Pasternak, AD/PD 2021: Phase 2 trial Investigating Ambroxol as a Treatment for Parkinson’s Disease Dementia
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!